RxDoctor Payments Data

Grace Kim, MD

Ophthalmology · Irvine, CANPI 1003101874

Payments from drug & device makers

$1,017in general payments, 2019–2025

Across 34 payments — averaging $29.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$141
  • Ivantis, Inc$140
  • AbbVie$138
  • Aerie Pharmaceuticals, Inc.$125
  • Alcon$118
  • Dompe US, Inc.$99
  • plus $256 from 7 others

What the payments were for

  • Food & beverage$1,00098%
  • Gifts$172%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,017 in reported general payments places this provider in the 45th percentile of 2,513 ophthalmology providers in California.

See all ophthalmology providers in California

Medicare billing

Part B allowed, 2024
$102,231
Medicare patients
344
Services billed
1,076

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RhopressaNetarsudil Mesylate176$72,075
XiidraLifitegrast24$28,092
LumiganBimatoprost51$27,051
MieboPerfluorohexyloctane/Pf25$26,769
VyzultaLatanoprostene Bunod70$21,890
SimbrinzaBrinzolamide/Brimonidine Tart60$17,135
RestasisCyclosporine12$15,950
Alphagan PBrimonidine Tartrate26$13,791
RocklatanNetarsudil Mesylat/Latanoprost27$10,603
Travoprost49$9,959
CequaCyclosporine11$8,456
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol45$6,867
IyuzehLatanoprost/Pf16$6,602
Latanoprost511$5,760
CombiganBrimonidine Tartrate/Timolol13$5,528

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aerie Pharmaceuticals, Inc.Rhopressa, Rocklatan$125$82,679203 claims
Bausch & Lomb Americas Inc.Xiidra, Miebo, Vyzulta$64$76,751119 claims
AbbVieLumigan, Restasis, Alphagan P, Combigan$138$62,320102 claims
AlconSimbrinza$118$17,13560 claims
Sun Pharmaceutical Industries Inc.Cequa$68$8,45611 claims
Thea Pharma Inc.Iyuzeh$45$6,60216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,513 ophthalmology providers in California.

Other ophthalmology in Irvine

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →